137215-12-4
Chemical Structure
Odiparcil
Synonym(s): SB-424323
- CAS No.: 137215-12-4
- Formula:C15H16O6S
- Molecular Weight:324.35
IUPAC Name: 4-methyl-7-(((2R,3R,4S,5S)-3,4,5-trihydroxytetrahydro-2H-thiopyran-2-yl)oxy)-2H-chromen-2-one
InChIKey: JRHNIQQUVJOPQC-AQNFWKISSA-N
SMILES: CC(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H](CS2)O)O)O)C=C1O3)=CC3=O
Biological Activity: Odiparcil (SB-424323) is an orally active β-D-xyloside derivative. Odiparcil can effectively divert the synthesis of cellular glycosaminoglycans (GAG) into secreted soluble species and reduce GAG accumulation. Odiparcil shows antithrombin and antiplatelet activity. Odiparcil can be used for the researches of metabolic and cardiovascular disease, such as mucopolysaccharidoses (MPS) and thrombosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Odiparcil | 99.23% | Odiparcil (SB-424323) is an orally active β-D-xyloside derivative. Odiparcil can effectively divert the synthesis of cellular glycosaminoglycans (GAG) into secreted soluble species and reduce GAG accumulation. Odiparcil shows antithrombin and antiplatelet activity. Odiparcil can be used for the researches of metabolic and cardiovascular disease, such as mucopolysaccharidoses (MPS) and thrombosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Odiparcil (Standard) | ≥98% | Odiparcil (Standard) is the analytical standard of Odiparcil (HY-10277). This product is intended for research and analytical applications. Odiparcil (SB-424323) is an orally active β-D-xyloside derivative. Odiparcil can effectively divert the synthesis of cellular glycosaminoglycans (GAG) into secreted soluble species and reduce GAG accumulation. Odiparcil shows antithrombin and antiplatelet activity. Odiparcil can be used for the researches of metabolic and cardiovascular disease, such as mucopolysaccharidoses (MPS) and thrombosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Entchev E, et al. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models. PLoS One. 2020 May 15;15(5):e0233032. [Content Brief]
- [2]. Toomey JR, et al. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. [Content Brief]
Keywords
